Immuron (IMRN) Cash & Equivalents (2016 - 2025)

Immuron (IMRN) has reported Cash & Equivalents for 10 consecutive years, with $28.3 billion the latest figure, recorded in Q3 2025.

• Quarterly Cash & Equivalents rose 24281014.48% year-over-year to $28.3 billion in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.3 billion (up 24281014.48% YoY) and the FY2025 annual result came in at $11.7 million, down 32.07% from the prior year.
• Cash & Equivalents advanced to $28.3 billion in Q3 2025 per IMRN's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IMRN reached as high as $28.3 billion in Q3 2025 and fell as low as $116573.2 in Q3 2024.
• A 5-year average of $2.0 billion and a median of $10.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 98.9% — and 2025, when it jumped 24281014.48%.
• Year by year, Cash & Equivalents stood at $17.7 million in 2021, then retreated by 11.73% to $15.6 million in 2022, then dropped by 22.39% to $12.1 million in 2023, then plunged by 32.07% to $8.2 million in 2024, then soared by 343715.72% to $28.3 billion in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $28.3 billion, $2.0 million, and $8.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.